Patents by Inventor Jacob Kihlstrom

Jacob Kihlstrom has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20120165346
    Abstract: The present invention relates to novel compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of A?-related pathologies such as Down's syndrome, ?-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.
    Type: Application
    Filed: December 20, 2011
    Publication date: June 28, 2012
    Applicant: ASTRAZENECA AB
    Inventors: Karin Kolmodin, Britt-Marie Swahn, Jacob Kihlström, Johan Lindström, Sofia Karlström, Marie Sundström, Stefan Von Berg
  • Publication number: 20100125087
    Abstract: The present invention relates to novel compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of A?-related pathologies such as Downs syndrome, ?-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.
    Type: Application
    Filed: November 13, 2009
    Publication date: May 20, 2010
    Applicant: AstraZeneca AB
    Inventors: Jorg HOLENZ, Sofia KARLSTROM, Jacob KIHLSTROM, Karin KOLMODIN, Laszlo RAKOS, Peter SODERMAN, Britt-Marie SWAHN, Stefan VON BERG, Fredrik VON KIESERITZKY
  • Publication number: 20100125081
    Abstract: The present invention relates to novel compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of A?-related pathologies such as Downs syndrome, ?-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.
    Type: Application
    Filed: November 13, 2009
    Publication date: May 20, 2010
    Applicant: ASTRAZENECA AB
    Inventors: Jorg HOLENZ, Sofia KARLSTROM, Jacob KIHLSTROM, Karin KOLMODIN, Johan LINDSTRÖM, Laszlo RAKOS, Didier ROTTICCI, Peter SODERMAN, Marie SUNDSTROM, Britt-Marie SWAHN, Stefan VON BERG
  • Publication number: 20090233930
    Abstract: This invention relates to novel compounds having the structural formula I below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.
    Type: Application
    Filed: November 20, 2006
    Publication date: September 17, 2009
    Applicants: ASTRAZENECA AB, ASTEX THERAPEUTICS LIMITED
    Inventors: Stefan Berg, Jeremy Burrows, Gianni Chessari, Miles Stuart Congreve, Johan Hedstrom, Sven Hellberg, Katharina Hogdin, Jacob Kihlstrom, Karin Kolmodin, Johan Lindstrom, Christopher Murray, Sahil Patel
  • Publication number: 20090192190
    Abstract: Compounds of formula I, wherein R1, Z, Y, M and R2 are as defined in the specification, pharmaceutically acceptable salts thereof, pharmaceutical composition containing the same, methods of using the same for therapeutic purposes and methods of making the same.
    Type: Application
    Filed: May 8, 2006
    Publication date: July 30, 2009
    Inventors: Helena Gyback, Markus Haeberlein, Catrin Jonasson, Jacob Kihlstrom, Hakan Molin, Berit Molin, Niklas Plobeck, Andreas Hettman, Jenny Viklund, Ulrika Yngve
  • Publication number: 20080293718
    Abstract: This invention relates to novel compounds having the structural formula I below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.
    Type: Application
    Filed: November 20, 2006
    Publication date: November 27, 2008
    Applicants: ASTRAZENECA AB, ASTEX THERAPEUTICS LIMITED
    Inventors: Stefan Berg, Jeremy Burrows, Gianni Chessari, Miles Stuart Congreve, Johan Hedstrom, Sven Hellberg, Katharina Hogdin, Jacob Kihlstrom, Karin Kolmodin, Johan Lindstrom, Christopher Murray, Sahil Patel
  • Publication number: 20080176862
    Abstract: This invention relates to novel compounds having the structural formula I below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.
    Type: Application
    Filed: December 19, 2007
    Publication date: July 24, 2008
    Applicants: ASTRAZENECA AB, ASTEX THERAPEUTICS LIMITED
    Inventors: Stefan Berg, Jorg Holenz, Sofia Karlstrom, Jacob Kihlstrom, Johan Lindstrom, Laszlo Rakos
  • Publication number: 20080058349
    Abstract: This invention relates to novel compounds having the structural formula I below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.
    Type: Application
    Filed: June 11, 2007
    Publication date: March 6, 2008
    Applicants: Astrazeneca AB, Astex Therapeutics Ltd
    Inventors: Stefan Berg, Jorg Holenz, Katharina Hogdin, Jacob Kihlstrom, Karin Kolmodin, Johan Lindstrom, Niklas Plobeck, Didier Rotticci, Fernando Sehgelmeble, Maria Wirstam
  • Publication number: 20080051420
    Abstract: This invention relates to novel compounds having the structural formula I below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.
    Type: Application
    Filed: June 11, 2007
    Publication date: February 28, 2008
    Applicants: AstraZeneca AB, Astex Therapeutics Ltd
    Inventors: Stefan Berg, Katharina Hogdin, Jacob Kihlstrom, Niklas Plobeck, Fernando Sehgelmeble, Maria Wirstam